Epstein RJ - Search Results

1

Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.

Yau T, Chan P, Wong H, Ng KK, Chok SH, Cheung TT, Lam V, Epstein RJ, Fan ST, Poon RT. Yau T, et al. Among authors: epstein rj. Oncology. 2007;72 Suppl 1:67-71. doi: 10.1159/000111709. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087184

2

The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Yau T, Yao TJ, Chan P, Epstein RJ, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT. Yau T, et al. Among authors: epstein rj. Cancer. 2009 Dec 1;115(23):5507-15. doi: 10.1002/cncr.24636. Cancer. 2009. PMID: 19701904 Free article.

3

Management of advanced hepatocellular carcinoma in the era of targeted therapy.

Yau T, Chan P, Epstein R, Poon RT. Yau T, et al. Liver Int. 2009 Jan;29(1):10-7. doi: 10.1111/j.1478-3231.2008.01916.x. Liver Int. 2009. PMID: 19120940 Review.

4

Evolution of systemic therapy of advanced hepatocellular carcinoma.

Yau T, Chan P, Epstein R, Poon RT. Yau T, et al. World J Gastroenterol. 2008 Nov 14;14(42):6437-41. doi: 10.3748/wjg.14.6437. World J Gastroenterol. 2008. PMID: 19030192 Free PMC article. Review.

5

Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy.

Yau T, Lo CY, Epstein RJ, Lam AK, Wan KY, Lang BH. Yau T, et al. Among authors: epstein rj. Ann Surg Oncol. 2008 Sep;15(9):2500-5. doi: 10.1245/s10434-008-0005-0. Epub 2008 Jun 26. Ann Surg Oncol. 2008. PMID: 18581185

6

PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success.

Wong H, Yau T, Chan P, Ng IO, Chan G, Hui P, Law WL, Lo CM, Hedley AJ, Epstein RJ. Wong H, et al. Among authors: epstein rj. Pathol Oncol Res. 2010 Mar;16(1):87-91. doi: 10.1007/s12253-009-9192-7. Epub 2009 Aug 20. Pathol Oncol Res. 2010. PMID: 19693706 Free PMC article.

7

Transient carcinoembryonic antigen elevations during adjuvant chemotherapy for colorectal cancer reflect the burden of residual micrometastatic disease.

Yau T, Wong H, Chan P, Chan T, Mak J, Epstein RJ. Yau T, et al. Among authors: epstein rj. Clin Colorectal Cancer. 2010 Apr;9(2):108-12. doi: 10.3816/CCC.2010.n.015. Clin Colorectal Cancer. 2010. PMID: 20378505

8

Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.

Chiu J, Tang V, Leung R, Wong H, Chu KW, Poon J, Epstein RJ, Yau T. Chiu J, et al. Among authors: epstein rj. Asian Pac J Cancer Prev. 2014 Jan;14(11):6585-90. doi: 10.7314/apjcp.2013.14.11.6585. Asian Pac J Cancer Prev. 2014. PMID: 24377572 Free article.

9

Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.

Wong H, Lau S, Cheung P, Wong TT, Parker A, Yau T, Epstein RJ. Wong H, et al. Among authors: epstein rj. BMC Cancer. 2014 Nov 10;14:826. doi: 10.1186/1471-2407-14-826. BMC Cancer. 2014. PMID: 25385074 Free PMC article.

10

Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.

Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Wong H, et al. Among authors: epstein rj. Br J Cancer. 2010 Apr 27;102(9):1391-6. doi: 10.1038/sj.bjc.6605655. Br J Cancer. 2010. PMID: 20424617 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

220 results

Search Page

Filters